摘要
临床上,小细胞肺癌(small cell lung cancer,SCLC)最常见的电解质紊乱是低钠血症,目前机制尚不清楚,以抗利尿激素分泌异常综合症(syndrome of inappropriate secretion of antidiuretic hormone,SIADH)为主,探索机制的发生有助于诊断与治疗,托伐普坦与其他治疗方案在低钠血症正常化方面是否更具有优势,目前仍需要进一步探讨,尿素、循环利尿剂、去甲环素、锂盐、氨柔比星、托伐普坦等不同治疗策略的选择为改善患者的预后提供可能。本文将对近几年SCLC并发低钠血症在治疗方案、预后因素等方面进行综述。
The most common electrolyte disorder in clinical small cell lung cancer(SCLC)is hyponatremia. Syndrome of inappropriate secretion of Antidiuretic hormone(SIADH)is the main part of this study,and exploring the mechanism is helpful for diagnosis and treatment. It is still necessary to further explore whether tolvaptan and other treatment plans are more advantageous in normalizing hyponatremia. The choice of different therapeutic strategies,such as urea,circulating diuretics,demecycline,lithium,amrubicin and tolvaptan,may improve the prognosis of patients. This article will review the treatment plan and prognostic factors of SCLC complicated with hyponatremia in recent years.
作者
荆扬飞
翟晋芳
李建强
JING Yangfei;ZHAI Jinfang;LI Jianqiang(Department of Critical Care Medicine,Xi′an Chest Hospital,Xi′an 710100,China)
出处
《实用医学杂志》
CAS
北大核心
2022年第11期1429-1433,共5页
The Journal of Practical Medicine
基金
山西省面上自然基金项目(编号:201901D111391)。
